How Academic Centers Coordinate High-Risk NMIBC Care

In this Urology Times Special Report series, Mark D. Tyson II, MD, MPH discusses high-risk non–muscle invasive bladder cancer (NMIBC) with Alexandra Drakaki, MD.

Mark D. Tyson II, MD, MPH, and Alexandra Drakaki, MD, work through what the POTOMAC results mean for who should actually receive the combination.

From same-day texts to shared clinic visits, 2 academic physicians describe the day-to-day mechanics of a urology-medical oncology partnership that actually works for patients.

How urologists partner with oncologists to deliver durvalumab plus BCG for high‑risk bladder cancer—keeping care local through communication.

Closing out the discussion, Mark D. Tyson II, MD, MPH, and Alexandra Drakaki, MD, talk tumor boards as an underused coordination tool, and Tyson shares where his comfort level stands on the newly approved durvalumab (Imfinzi)-BCG combination.